Skip to main content
TipRanks
Go Ultimate75% OFF

InMode (154) AI Stock Analysis

3 Followers
DE:154

InMode

(Frankfurt:154)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Conservative balance sheetExtremely low leverage gives InMode substantial financial flexibility to fund product development, sales expansion, and shareholder returns without relying heavily on borrowing. The large equity base also improves resilience if demand remains uneven or profitability takes longer to recover.
Negative Factors
Sustained revenue declineRepeated revenue contraction signals that weaker demand or slower system sales is not limited to a single quarter. Continued top-line pressure can reduce operating leverage, constrain investment capacity, and make a durable return to prior growth rates more difficult.

InMode (154) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%20%DE:154-0.13%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 741.17M
Dividend Yield
―
Average Volume (3M)
118
Price to Earnings (P/E)
10.5
Beta (1Y)
0.41
Revenue Growth
-2.48%
EPS Growth
-47.17%
Country
Germany
Employees
660
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

InMode Business Overview & Revenue Model

Company Description

InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical s...

InMode Earnings Call Summary

Earnings Call Date:May 06, 2026(Q1-2026)|% Change Since:-2.89%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentNeutral

The call contained a mix of modest top-line progress and strategic positives (5% revenue growth, strong cash balance, product launches, sales reorganization and share repurchases) offset by notable margin compression, rising operating expenses and declines in EPS. Management provided steady full-year guidance and described early signs of stabilization in the U.S., but profitability pressures and macroeconomic headwinds temper the outlook. International and product development initiatives offer upside, while near-term margin and demand uncertainty are the primary negatives.

Positive Updates

Revenue Growth
Total revenue of $82.0M in Q1 2026, up 5% from $77.9M in Q1 2025, driven primarily by stronger U.S. performance.

Negative Updates

Gross Margin Compression
GAAP gross margin fell to 75% in Q1 2026 from 78% in Q1 2025; non-GAAP gross margin fell to 75% from 79% a year ago, with management warning new laser platforms may put additional pressure on gross margins.

Company Guidance

The company reiterated 2026 guidance calling for revenue of $365–$375 million, non‑GAAP gross margin of 74%–76%, non‑GAAP income from operations of $73–$78 million, and non‑GAAP diluted EPS of $1.33–$1.38; for context, Q1 results included $82.0 million revenue, 75% non‑GAAP gross margin, 17% non‑GAAP operating margin, $0.25 non‑GAAP diluted EPS and $15.4 million cash from operations, while the balance sheet held $537.2 million in cash/marketable securities and the company returned capital via $127.4 million repurchases in 2025 plus $52.7 million year‑to‑date in 2026 (3.86 million shares).

InMode Risk Analysis

InMode disclosed 61 risk factors in its most recent earnings report. InMode reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

0 New Risks

InMode Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:154 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CNMDCNMD63Neutral$1.43B19.847.07%―1.93%16.93%
ESTAESTA61Neutral$2.11B-55.39-203.65%―38.25%55.14%
RCELRCEL60Neutral$528.80M-14.14146.38%―16.96%34.83%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SRTSSRTS45Neutral$37.86M-2.37-38.65%―-53.33%-429.93%
IARTIART43Neutral$1.05B82.601.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

0%100%200%300%DE:154CNMDIARTRCELSRTSESTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:154 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:154Inmode11.75-0.34-2.81%
CNMDConmed Corporation48.017.3818.16%
IARTIntegra Lifesciences13.862.8125.43%
RCELAvita Medical Ltd16.8312.99338.28%
SRTSSensus Healthcare, Inc.2.30-1.63-41.48%
ESTAEstablishment Labs Holdings70.804.757.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.